¿ÏÀü ÀýÁ¦µÈ IB ºñ¼Ò¼¼Æ÷¾Ï¿¡¼­ Àç¹ßÀÇ ¿¹ÈÄÀÎÀÚ·ÎÀÇ ÀåÃø´Á¸· ħ¹ü
Visceral Pleural Invasion as a Prognostic Factor for Recurrence in Resected IB Non-small Cell Lung Cancer

´ëÇÑÈäºÎ¿Ü°úÇÐȸÁö 2009³â 42±Ç 5È£ p.610 ~ p.614

±è¼®(Kim Seok) - ´ë±¸°¡Å縯´ëÇб³º´¿ø ÈäºÎ¿Ü°ú
¹Ú±â¼º(Park Ki-Sung) - ´ë±¸°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ´ë±¸°¡Å縯´ëÇк´¿ø ÈäºÎ¿Ü°úÇб³½Ç
±ÝÀ±¼·(Kum Yoon-Seup) - ´ë±¸°¡Å縯´ëÇб³º´¿ø º´¸®°ú
À̼·(Lee Sub) - ´ë±¸°¡Å縯´ëÇб³º´¿ø ÈäºÎ¿Ü°ú
¹èÁöÈÆ(Bae Chi-Hoon) - ´ë±¸°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ´ë±¸°¡Å縯´ëÇк´¿ø ÈäºÎ¿Ü°úÇб³½Ç
Çö´ë¼º(Hyun Dae-Sung) - ´ë±¸°¡Å縯´ëÇб³º´¿ø ³»°úÇб³½Ç

Abstract

¹è°æ: ¿ÏÀü ÀýÁ¦µÈ IB ºñ¼Ò¼¼Æ÷¾Ï¿¡¼­ Ç׾Ͽä¹ýÀÇ ¹Ýµå½Ã ÇÊ¿äÇÑ°¡¿¡ ´ëÇÑ ¿©·¯ º¸°í°¡ ÀÖ´Ù. ±×·¡¼­ º» ¿¬±¸´Â ¿ÏÀü ÀýÁ¦µÈ IB ºñ¼Ò¼¼Æ÷¾Ï ȯÀÚ¿¡¼­ Àç¹ß¿¡ °ü¿©ÇÏ´Â ¿¹ÈÄÀÎÀÚ¸¦ ã°í Ç׾Ͽä¹ýÀÇ Çʿ伺À» ¾Ë¾Æº¸¾Ò´Ù.

´ë»ó ¹× ¹æ¹ý: 1997³âºÎÅÍ 2006³â±îÁö ¸ðµÎ 48¸íÀÇ È¯ÀÚ¸¦ ÈÄÇâÀûÀ¸·Î Á¶»çÇÏ¿´´Ù. Àüü»ýÁ¸À²°ú ¹«º´»ýÁ¸À²À» À§ÇØ Kaplan-Meier method¸¦ »ç¿ëÇÏ¿´°í ´Üº¯·® ºÐ¼®Àº log rank, ´Ùº¯·®ºÐ¼®Àº Cox ȸ±Í¸ðÇüÀ» »ç¿ëÇÏ¿´´Ù.

°á°ú: ÃßÀûÁß¾Ó°ªÀº 48°³¿ù, 5³â Àüü»ýÁ¸À²Àº 55.9%, 5³â ¹«º´ »ýÁ¸À²Àº 48.6%¿´´Ù. ´Üº¯·® ºÐ¼®¿¡¼­ ÀåÃø´Á¸·°ú ÀÓÆÄÇ÷°üħ¹üÀÌ Àç¹ß¿¡ À¯ÀÇÇÑ ÀÎÀÚ¿´°í, ´Ùº¯·® ºÐ¼®¿¡¼­´Â ÀåÃø´Á¸·Ä§¹üÀÌ ¿¹ÈÄÀÎÀÚ¿´´Ù. ¶ÇÇÑ ÀåÃø´Á¸·, ÀÓÆÄÇ÷°ü ħ¹ü Áß ÇÑ °³ ÀÌ»óÀÇ °æ¿ì, ¾ø´Â °æ¿ì¿Í ºñ±³ÇÏ¿© Àüü »ýÁ¸À²¿¡¼­ ÀÇ¹Ì ÀÖ´Â Â÷ÀÌ°¡ ÀÖ¾ú´Ù.

°á·Ð: ÀåÃø´Á¸·Ä§¹üÀº Àç¹ß ¹× »ýÁ¸¿¡ °ü¿©ÇÏ´Â ºÒ·®ÇÑ ¿¹ÈÄÀÎÀÚÀ̸ç, Ç׾Ͽä¹ýÀÌ ÇÊ¿äÇÑ È¯ÀÚ¸¦ ¼±ÅÃÇÒ ¶§ µµ¿ò µÇ´Â ÀÎÀÚ·Î »ý°¢µÈ´Ù.
Background: Several trials have reported on whether adjuvant chemotherapy for resected stage IB non-small cell lung cancer is needed. The aim of our study was to investigate prognostic factors for recurrence to help identify patients who should receive adjuvant chemotherapy.

Material and Method: We reviewed the cases of 48 stage IB non-small cell lung cancer patients between 1997 and 2006. Disease-free survival and overall survival rates were calculated by the Kaplan-Meier method. Univariate analysis was performed with the log rank test and multivariate analysis was done using Cox¡¯s proportional hazard model.

Result: The median follow-up time was 48 months. The overall survival rate was 55.9%, and the disease-free survival rate was 48.6%. Of 8 variables, two factors, visceral pleural invasion and lymphovascular invasion, were prognostic factors of disease-free survival (univariate analysis). Visceral pleural invasion was a significant prognostic factor in multivariate analysis, and overall survival in compared one or more variable such as visceral pleural invasion or, and lymphovascular invasion with the other variables.

Conclusion: Visceral pleural invasion was identified as a poor prognostic factor and it may help select which patients will benefit from adjuvant chemotherapy in addition to more comprehensive follow-up.

Å°¿öµå

Á¾¾çº´±â, º¸Á¶¿ä¹ý, ÀåÃø´Á¸·Ä§¹ü
Neoplasm stage, Adjuvant therapy, Visceral pleural invasion
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
Visceral pleural invasion was identified as a poor prognostic factor and it may help select which patients will benefit from adjuvant chemotherapy
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå